Praxis Precision Medicines - PRAX Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRAX, but not buy additional shares or sell existing shares.
View PRAX analyst ratings or view top-rated stocks.

5 brokerages have issued 12-month price targets for Praxis Precision Medicines' stock. Their PRAX share price forecasts range from $4.00 to $18.00. On average, they anticipate the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,144.4% from the stock's current price.
View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts.

Praxis Precision Medicines' stock was trading at $2.38 at the start of the year. Since then, PRAX stock has decreased by 64.5% and is now trading at $0.8438.
View the best growth stocks for 2023 here.

Praxis Precision Medicines saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,450,000 shares, an increase of 37.8% from the February 28th total of 3,230,000 shares. Based on an average daily volume of 1,970,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 10.7% of the company's shares are sold short.
View Praxis Precision Medicines' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our PRAX earnings forecast.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its quarterly earnings data on Tuesday, February, 7th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by $0.14.

(PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX."

Praxis Precision Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (5.45%), Verition Fund Management LLC (3.19%), EcoR1 Capital LLC (3.03%), Bank of America Corp DE (2.89%), Vida Ventures Advisors LLC (3.12%) and Geode Capital Management LLC (1.32%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly.
View institutional ownership trends.

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRAX stock can currently be purchased for approximately $0.84.

Praxis Precision Medicines (NASDAQ:PRAX) has a market capitalization of $44.21 million. The company earns $-214,030,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

The company employs 139 workers across the globe.

Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The official website for the company is www.praxismedicines.com. The company can be reached via phone at 617-300-8460 or via email at investors@praxismedicines.com.